PE20030206A1 - OPHTHALMIC COMPOSITION - Google Patents

OPHTHALMIC COMPOSITION

Info

Publication number
PE20030206A1
PE20030206A1 PE2002000483A PE2002000483A PE20030206A1 PE 20030206 A1 PE20030206 A1 PE 20030206A1 PE 2002000483 A PE2002000483 A PE 2002000483A PE 2002000483 A PE2002000483 A PE 2002000483A PE 20030206 A1 PE20030206 A1 PE 20030206A1
Authority
PE
Peru
Prior art keywords
ophthalmic
mpa
treatment
octilphenoxy
ketotyphene
Prior art date
Application number
PE2002000483A
Other languages
Spanish (es)
Inventor
Saunier Maggy Babiole
Jean-Claude Bizec
Andrea Fetz
Christian Schoch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20030206A1 publication Critical patent/PE20030206A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

QUE COMPRENDE: a)0,005% A 5% DEL PESO TOTAL DE UN FARMACO OFTALMICO SELECCIONADO DE: DICLOFENACO, PREDNISOLONA, CETOTIFENO, ACIDO ASCORBICO, RETINAL, O SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS; b)0,05% A 10% DE UN COMPUESTO DE POLISACARIDO LINEAL COMO HIALURONATO DE SODIO; POR LO MENOS UNO DE LOS SIGUIENTES COMPONENTES: c)AGENTE MEJORADOR DE TONICIDAD; d)REGULADOR DEL pH; e)CONSERVADOR TAL COMO CLORURO DE BENZALCONIO; f)UN PRODUCTO DE REACCION DE ACEITES NATURALES O HIDROGENAODS Y ETILENGLICOL COMO SOLUBILIZANTE, EN PARTICULAR OCTILFENOXI-POLI(ETILENOXI)ETANOL; g)AGENTE FORMADOR DE COMPLEJO; Y/O h) VEHICULO OFTALMICO. DONDE, LA VISCOSIDAD DE LA COMPOSICION ES DE 500 mPa A 2 000 mPa ENTRE 20°C Y 25°C, LA CUAL TIENE APLICACION EN EL TRATAMIENTO DE ENFERMEDADES/DESORDENES OFTALMICOS COMO: GLAUCOMA, MIOSIS, ANESTESIA O INFECCIONES OCASIONADAS POR VIRUS O MICROORGANISMOS; ASI COMO EN LA PREVENCION Y TRATAMIENTO DE CONJUNTIVITIS ALERGICAWHICH INCLUDES: a) 0.005% TO 5% OF THE TOTAL WEIGHT OF A SELECTED OPHTHALMIC DRUG FROM: DICLOFENAC, PREDNISOLONE, KETOTYPHENE, ASCORBIC ACID, RETINAL, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEM; b) 0.05% TO 10% OF A LINEAR POLYSACCHARIDE COMPOUND SUCH AS SODIUM HYALURONATE; AT LEAST ONE OF THE FOLLOWING COMPONENTS: c) TONICITY IMPROVING AGENT; d) pH REGULATOR; e) CONSERVATIVE SUCH AS BENZALCONIUM CHLORIDE; f) A REACTION PRODUCT OF NATURAL OILS OR HYDROGENES AND ETHYLENE GLYCOL AS A SOLUBILIZER, IN PARTICULAR OCTILPHENOXY-POLY (ETHYLENOXY) ETHANOL; g) COMPLEX FORMING AGENT; AND / OR h) OPHTHALMIC VEHICLE. WHERE, THE VISCOSITY OF THE COMPOSITION IS FROM 500 mPa TO 2 000 mPa BETWEEN 20 ° C AND 25 ° C, WHICH IS APPLICABLE IN THE TREATMENT OF OPHTHALMIC DISEASES / DISORDERS SUCH AS: GLAUCOMA, MIOSIS, ANESTHESIA OR INFECTIONS CAUSED BY VIRUSES; AS WELL AS IN THE PREVENTION AND TREATMENT OF ALLERGIC CONJUNCTIVITIS

PE2002000483A 2001-06-08 2002-06-07 OPHTHALMIC COMPOSITION PE20030206A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01113959 2001-06-08
EP01113958 2001-06-08
EP01115096 2001-06-21
EP01115097 2001-06-21

Publications (1)

Publication Number Publication Date
PE20030206A1 true PE20030206A1 (en) 2003-04-09

Family

ID=27440131

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000483A PE20030206A1 (en) 2001-06-08 2002-06-07 OPHTHALMIC COMPOSITION

Country Status (9)

Country Link
EP (1) EP1404370A2 (en)
JP (1) JP2005508866A (en)
CN (1) CN1514735A (en)
AR (1) AR034371A1 (en)
AU (1) AU2002314149A1 (en)
BR (1) BR0210139A (en)
CA (1) CA2449213A1 (en)
PE (1) PE20030206A1 (en)
WO (1) WO2002100437A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002345015A1 (en) * 2001-06-08 2002-12-23 Novartis Pharma Gmbh Ophthalmic once-a-day composition
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
JP2004143155A (en) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd Ophthalmic solution
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
ES2431640T3 (en) * 2003-08-21 2013-11-27 Sucampo Ag Ophthalmic composition comprising isopropyl ester of unoprostone and a viscosity agent
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP2007518804A (en) * 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド Composition for topical ophthalmic treatment preferably containing triamcinolone acetonide and hyaluronic acid
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
DE102005035986B4 (en) * 2005-07-28 2009-10-15 Bausch & Lomb Incorporated Sterile drippable multiphase emulsifier-free ophthalmic preparation
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CN100408046C (en) * 2005-12-22 2008-08-06 涂家生 Macrolide antibiotics sodium hyaluronate eye transfer system
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
CA2813734A1 (en) * 2010-10-04 2012-04-12 Activbiotics Pharma, Llc Use of rifalazil and analogues thereof to treat ocular disorders
KR101412776B1 (en) * 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 Eye drop composition for treating keratoconjunctivitis and preparation method of the same
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
BR112019002967A2 (en) 2016-08-19 2019-05-14 Orasis Pharmaceuticals Ltd. ophthalmic pharmaceutical composition, methods of correcting presbyopia, reducing pupil size, inducing miosis, increasing depth of field, decreasing the magnitude of higher order aberrations, and improving near and far uncorrected visual acuity , implant and kit.
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (en) * 1985-04-05 1991-07-17 Fidia Farmaceutici Topical compsn. contg. hyaluronic acid deriv. as vehicle
RU2089191C1 (en) * 1994-01-28 1997-09-10 Научно-производственная фирма "Нарт" Method of prolongation of physiological effect of thymolol with respect to intraocular pressure decreasing
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
JPH1160505A (en) * 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd Antiseptic composition
DE19923829A1 (en) * 1999-05-17 2000-11-23 Ulrich Kluegel Complex of hyaluronate, active ingredient and water, useful as topical pharmaceutical or cosmetic composition, is stable and has high content of active agent
US6777429B1 (en) * 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition

Also Published As

Publication number Publication date
JP2005508866A (en) 2005-04-07
AU2002314149A1 (en) 2002-12-23
AR034371A1 (en) 2004-02-18
WO2002100437A2 (en) 2002-12-19
EP1404370A2 (en) 2004-04-07
CN1514735A (en) 2004-07-21
CA2449213A1 (en) 2002-12-19
WO2002100437A3 (en) 2003-04-24
BR0210139A (en) 2004-06-08

Similar Documents

Publication Publication Date Title
PE20030206A1 (en) OPHTHALMIC COMPOSITION
WO2021147236A9 (en) Use of substituted aminopropionate compound in treatment of sars-cov-2 infections
TW200700070A (en) Enhanced bimatoprost ophthalmic solution
EA200700109A1 (en) METHODS OF TREATMENT OF OPHTHALMOLOGICAL CONDITIONS (OPTIONS)
JPWO2007108541A1 (en) Ophthalmic composition containing xanthan gum and glucose
AR064420A1 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AN EFFECTIVE AMOUNT OF ANALOGS OF 6-AMINOIMIDAZO [1,2B] PIRIDAZINAS, USEFUL FOR THE TREATMENT OF GLAUCOMA AND / OR CONTROL THE NORMAL OR ELEVATED INTRAOCULAR PRESSURE (IOP).
RU2010142353A (en) WATER PHARMACEUTICAL COMPOSITIONS CONTAINING BORATE-POLYOLIC COMPLEXES
CN103068364B (en) Bimatoprost without preservative and timolol solution
KR101322527B1 (en) Eye drop preparation comprising xanthan gum and terpenoid
AR032138A1 (en) DERIVATIVES OF 6-HYDROXY-INDAZOL, AN OPHTHALMIC COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF GLAUCOMA
CY1110644T1 (en) 5,6,7-Trihydroxyheptanoic acid and its analogues for the treatment of ophthalmic diseases related to hypercapillary and angiogenic diseases
JP2021107464A (en) Ophthalmic composition
MX2023011377A (en) 1,3-substituted cyclobutyl derivatives and uses thereof.
MX2022012575A (en) Compounds for treating huntington's disease.
ES2177543T3 (en) METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE EYE OF MAMMALS BY ADMINISTRATION OF MUSCARINIC ANTAGONISTS.
PE20030064A1 (en) PHARMACEUTICAL OPHTHALMIC COMPOSITIONS
CO2020009992A2 (en) Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
JP2005162747A (en) Ophthalmic composition
JP4849288B2 (en) Eye drops and tear film stabilizer
JP2005247802A (en) Eye drops
KR960700711A (en) Medicine for treating or preventing cerebrovascular diseases
JP2011105706A (en) Ophthalmic agent
JP2015010088A (en) Multicomponent-containing eye drops
ATE428412T1 (en) TREATMENT OF EYE DISEASES WITH UREA AND UREA DERIVATIVES
EA200500187A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TOXIC NEUROPATHY

Legal Events

Date Code Title Description
FC Refusal